A Phase I/II Trial of CRLX101, a Nanoparticle Camptothecin With Olaparib in Patients With Relapsed/Refractory Small Cell Lung Cancer

Trial Profile

A Phase I/II Trial of CRLX101, a Nanoparticle Camptothecin With Olaparib in Patients With Relapsed/Refractory Small Cell Lung Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 May 2017

At a glance

  • Drugs Camptothecin (Primary) ; Olaparib (Primary)
  • Indications Small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 04 Aug 2016 According to a Cerulean Pharma media release, first patient has been dosed in this trial second quarter 2016.
    • 10 May 2016 Top-line data from this trial is expected in the first half of 2017, according to a Cerulean Pharma media release.
    • 16 Mar 2016 According to a Cerulean Pharma media release, clinical data of this trial will be presented at the 2016 American Association for Cancer Research (AACR) Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top